Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

Callisto Pharmaceuticals

Status and phase

Completed

Phase 2

Phase 1

Conditions

Multiple Myeloma

Treatments

Drug: Atiprimod

Study type

Interventional

Funder types

Industry

Identifiers

NCT00086216

CP-101

efficacy

research markers

pharmacokinetics

Details and patient eligibility

About

This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.

Full description

This is a multi-center, open-label, dose escalation study intended to identify the MTD of atiprimod alone and the MTD of atiprimod when given in combination with ursodiol. The atiprimod dose will be escalated in sequential cohorts. Ten dose levels of atiprimod are planned for the atiprimod alone dose escalation: 30, 60, 90, 120, 180, 240, 300, 360, 420, and 480 mg/day to be given orally. Six dose levels of atiprimod are planned for the atiprimod in combination with ursodiol dose escalation: 180, 240, 300, 360, 420, and 480 mg/day to be given orally. The dose of ursodiol will remain constant for all cohorts (300 mg ursodiol orally three times a day everyday). Up to 105 patients will participate depending on the level at which toxicity is observed. Patients will be assigned to dose level in the order of study entry.

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

documented history of multiple myeloma,
failed at least two prior regimens for multiple myeloma,
18 years of age or older,
ECOG(Zubrod)PS of 0 to 2,
screening evaluation for determining eligibility prior to enrollment,
signed informed consent form,

Exclusion criteria

concomitant therapy medications including corticosteroids or other chemotherapy that is or may be active against myeloma ,
renal insufficiency (serum creatinine levels of > 2mg/dL),
mucosal bleeding,
any condition which in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study.
clinically relevant active infection or co-morbid medical conditions.
prior malignancy(within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient is has been disease-free for at least 3 years.
patients with non-secretory myeloma.
as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be excluded.